Regulatory Work to Secure Licence Variation for anastrozole
A Addendum Notice
by NHS ENGLAND
- Source
- Find a Tender
- Type
- Contract (Services)
- Duration
- not specified
- Value
- ___
- Sector
- HEALTH
- Published
- 19 Jan 2022
- Delivery
- not specified
- Deadline
- n/a
Related Terms
Location
1 buyer
- NHS England Leeds
Description
This Tender is solely for the work involved to apply for and implement a major (type II) MHRA Marketing Authorisation variation to add a new clinical indication for anastrozole. The successful Bidder will be responsible for ensuring that all relevant MHRA conditions and documentation for the Marketing Authorisation variation are met and submitted within the time limits agreed with the Authority.
Ammendments to Previous Notice
2. Short description
This Tender is solely for the work involved to apply for and implement a major (type II) MHRA Marketing Authorisation variation to add a new clinical indication for anastrozole. The successful Bidder will be responsible for ensuring that all relevant MHRA conditions and documentation for the Marketing Authorisation variation are met and submitted within the time limits agreed with the Authority. In return the Authority will fund actual and reasonably incurred costs associated with obtaining this licence variation only. Full details can be found on the Atamis portal: https://health-family.force.com/s/Welcome Closing date for submissions is 7th February 2022 at 13:00
3. Deadline for EOI date
Mon Jan 31 Feb 7 00:00:00 2022
4. Tender opening date
Tue Feb 1 8 00:00:00 2022
CPV Codes
- 85149000 - Pharmacy services
Other Information
In return the Authority will fund actual and reasonably incurred costs associated with obtaining this licence variation only.Full details can be found on the Atamis portal: https://health-family.force.com/s/Welcome Closing date for submissions is 31st January 2022 at 13:00 ** PREVIEW NOTICE, please check Find a Tender for full details. **
Reference
- ocds-h6vhtk-02de26
- FTS 001642-2022